The few studies investigating the difference in magnitude of the association between OC use and breast cancer risk depending on genetic predisposition have primarily focused on carriers of the BRCA1 and BRCA2 mutations [8–10]. The gene discussed is BRCA1; the disease is breast carcinoma.